Quantcast

Latest osteomalacia Stories

2010-06-21 07:00:00

SAN DIEGO, June 21 /PRNewswire/ -- Enobia Pharma today announced positive interim data from a clinical study of ENB-0040, a bone targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). After 12 weeks of treatment with ENB-0040, children with HPP showed marked improvements in bone mineralization and function including increases in strength, endurance and mobility and reduction in pain. These findings were presented by Dr. Michael Whyte at ENDO...

2010-03-29 16:00:00

MONTREAL, March 29 /PRNewswire/ -- Enobia Pharma Inc. unveiled findings from the first hypophosphatasia (HPP) self-reported patient survey intended to evaluate the burden of illness associated with HPP at the 2010 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting. An update on the clinical program for ENB-0040, Enobia's investigational enzyme replacement therapy for HPP, was also presented at the meeting by Cheryl Rockman-Greenberg, MD, Medical Director, Child...

1721a159fa4d91b8c2066865ee4cff041
2010-01-23 07:30:00

The growing number of hours children now spend indoors surfing the Web, watching television or playing video games may be linked to a resurgence of rickets, according to a new study published in the current issue of the British Medical Journal. Rickets is caused by chronic vitamin D deficiencies, which can result after long periods without natural sunlight or an inadequate diet. Children suffering from the bone-bending disease can develop painful and deformed bow-legs that do not properly...

2009-11-03 07:01:00

MONTREAL, Nov. 3 /PRNewswire/ -- Enobia Pharma announced today the initiation of a Phase 2 clinical study of ENB-0040, a bone-targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). The six-month study will assess the safety, efficacy and pharmacokinetics of ENB-0040 in up to 12 children with HPP. This study follows the recent presentation of positive Phase 2 data in infants, which showed that, in the majority of patients, six months of...

2009-09-14 07:00:00

DENVER, Sept. 14 /PRNewswire/ -- Enobia Pharma today announced positive data from a clinical study of ENB-0040, a bone targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). After six months of treatment with ENB-0040, four of five severely affected patients showed marked improvements in bone mineralization, correction of skeletal defects, better respiratory function, including weaning from assisted ventilation, and cognitive and motor...

2009-08-10 08:00:00

MONTREAL, Aug. 10 /PRNewswire/ -- Enobia Pharma, an emerging biotech company focused on developing novel therapeutics for serious bone disorders, today announced that it raised US$50 million from its current investors in a Series C financing. The proceeds will be used primarily to fund the ongoing development program for ENB-0040, Enobia's enzyme replacement therapy (ERT) for hypophosphatasia (HPP), a rare and potentially deadly genetic bone disorder for which there is no currently approved...

2009-03-03 08:03:00

MONTREAL, March 3 /PRNewswire/ -- Enobia Pharma, an emerging Canadian biotech company focused on developing novel therapeutics for serious bone disorders, today announced completion of target enrollment in its pilot clinical trial in infants suffering from a severe form of hypophosphatasia. Enobia is investigating Enzyme Replacement Therapy (ERT) with ENB-0040 for the treatment of this rare and often crippling genetic bone disorder for which there is no approved treatment. ENB-002-08 is an...

2008-12-24 11:25:39

Pregnant women who are vitamin D deficient are at an increased risk for delivering a baby by Cesarean section, U.S. researchers said. Researchers from Boston University School of Medicine and Boston Medical Center said at the turn of the 20th century, women commonly died in childbirth due to rachitic pelvis, rickets of the pelvis. While rickets virtually disappeared with the discovery of vitamin D, recent reports suggest vitamin D deficiency is widespread in industrialized nations. The...

2008-12-23 16:01:57

Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) found that pregnant women who are vitamin D deficient are also at an increased risk for delivering a baby by caesarean section as compared to pregnant women who are not vitamin D deficient. These findings currently appear on-line in the Journal of Clinical Endocrinology & Metabolism. At the turn of the 20th century, women commonly died in childbirth due to "rachitic pelvis" rickets of the pelvis....

2008-12-01 10:48:00

Baby Girl with Hypophosphatasia Treated With ENB-0040 at Children's Hospital, Health Sciences Centre in Winnipeg MONTREAL, Dec. 1 /PRNewswire/ -- Enobia Pharma, an emerging Canadian biotech company focused on developing novel therapeutics for serious bone disorders, today announced that the first infant patient in its clinical program for hypophosphatasia was dosed. Enobia is investigating Enzyme Replacement Therapy (ERT) with ENB-0040 for the treatment of this rare and often crippling...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related